The molecular genetics of cardiovascular disease: Clinical implications

Journal of Internal Medicine

Volumn 253, Issue 2, 2003, Pages 120-127

  Stephens, Jeffrey W ^a   Humphries, S E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Coronary heart disease; Diagnosis; Environment; Genes; Polygenic

Indexed keywords

APOLIPOPROTEIN E; CYTOKINE; INTERLEUKIN 6; LIPOPROTEIN LIPASE;

CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC ANALYSIS; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

APOLIPOPROTEINS E; CORONARY DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; LIPOPROTEIN LIPASE; SMOKING;

EID: 0037318641     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01104.x     Document Type: Review

References (43)

1. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipo-protein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996; 16: 1250-5.
2. Doll R, Hill AB. Mortality of British doctors in relation to smoking: observation on coronary thrombosis. In: Haenzel W. ed. Epedemiological Approaches to the Study of Cancer and Other Chronic Disease. National Cancer Institute Monograph No. 19. Bethesda. MD. USA: US Department of Health, Education and Welfare, 1966; 99: 205-68.
3. Boer JM, Fesken EJ, Verschuren WM, Seidell JC, Kromhout D. The joint impact of family history of myocardial infarction and other risk factors on 12-year coronary heart disease mortality. Epidemiology 1999; 10: 767-70.
4. Hawe E, Talmud PJ, Miller GJ, Humphries SE. Family history is a coronary heart disease risk factor in the second Northwick Park Heart Study. Ann Hum Genet, in press.
5. Marenberg ME, Risch N, Berkman LF, Floderus B, de Flaire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-6.
6. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kaousdian S, Kannell WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-8.
7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
8. Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
9. Ross R. Atherosclerosis - an inflammatory disease. New Engl J Med 1999; 340: 115-26.
10. Heath KE, Humphries SE, Middleton-Price H, Boxer M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet 2001; 9: 244-52.
11. Talmud PJ, Humphries SE. Gene:environment interaction in lipid metabolism and effect on coronary heart disease. Curr Opin Lipid 2002; 13: 149-54.
12. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 1988; 8: 1-21.
13. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day INM, Miller GJ. ApoE4 increases the risk of coronary heart disease in middle-aged men who smoke: Second Northwick Park Heart Study. Lancet 2001; 358: 115-9.
14. Kessler C, Spitzer C, Stauske D et al. The apolipoprotein E and the beta-fibrinogen G/A-455 gene polymorphisms are associated with ischaemic stroke and latge-vessel disease. Arterioseler Thromb Vasc Biol 1997; 17: 2880-4.
15. Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein epsilon allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocsrdial infarction: a sub-study of the Scandinavian Simvastatin Survival Study. Circulation 2000; 101: 1366-71.
16. Smith JD, Miyata M, Poulin SE, Neveux LM, Craig WY. The relationship between apoliporotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent. Int J Clin Lab Res 1998; 28: 116-21.
17. Cullen P, Cingarella A, Brennhausen B, Mohr S, Assmann G, von Eckardstein A. Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human derived monocyte-derived macrophages. J Clin Invest 2000; 101: 1607-77.
18. Talmud PJ, Hawe E, Miller GJ, Analysts of gene-enviroment interaction in coronary disease: lipoprotein lipase and smoking as examples. Ital Heart J 2002; 3: 6-9.
19. Olivecrona G, Olivecrona T. Triglyceride lipase and atherosclerosis. Curr Opin Lipidol 1995; 6: 291-305.
20. Beisiegel U, Weber W, Bengtsson-Oliveecrono G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991; 88: 8342-6.
21. Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene: effects of plasma lipids and atherosclerosis. Atherosclerosis 1997; 13: 145-59.
22. Talmud PJ, Bujac SR, Hall S, Miller GJ, Humphries SE. Substitution of asparagine for aspartic acid at residue 9 (D9N) of lipoprotein lipase markedly augments risk of ischaemic heart disease in male smokers. Atherosclerosis 2000; 149: 75-81.
23. Keller ET, Wanagat J, Ershler WM. Molecular and cellular biology of interleukin-6 and its receptor. Frontiers in Bioscience 1996; 1: 340-57.
24. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36.
25. Mohamed-Ali V, Goodrick S, Rawesh A et al. Human subcutaneous adipose tissue releases il-6 but not TNF-a in vivo. J Clin Endo Metab 1997; 82: 4196-200.
26. Ridker PM, Hennekens CH, Buring JE, Rifai N, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEJM 2000; 342: 836-43.
27. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
28. Gabriel AS, Ahnve S, Wretlind B, Martinson A, IL-6 and IL-1 receptor antagonists in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction. JIM 2000; 248: 61-6.
29. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
30. UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasound surveillance for small abdominal aortic aneurysms. Lancet 1998; 352: 1649-55.
31. Jones KG, Brull DJ, Brown LC et al. Interleukin-6, (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260-5.
32. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 - 174G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22: 2243-52.
33. Georges JL, Loukaci V, Poirer O et al. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. J Mol Med 2001; 79: 300-5.
34. Humphries SE, Donati MB. Analysis of gene-enviroment interaction in coronary artery disease. Ital Heart J 2002; 3: 3-5.
35. Allen DR, Browse NL, Rutt DL, Butler L, Fletcher C. The effect of cigarette smoke, nicotine and carbon monoxide on the permeability of the arterial wall. J Vasc Surg 1998; 7: 139-52.
36. Blann AD. The acute influence of smoking on the endothelium. Atherosclerosis 1992; 96: 249-50.
37. Loew GD. Blood viscosity and cardiovascular risk. Curr Opin Lipidol 1993; 4: 283-7.
38. Eliasson B, Mero N, Taskinen MR, Smith U. The insulin resistance syndrome and postprandial lipid intolerance in smokers. Astherosclerosis 1997; 129: 79-88.
39. Lowe GDO, Rumley A. Coagulation, fibrinolysis and cardiovascular disease. Fibrinolysis & Proteolysis 1999; 13: 91-8.
40. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GDO. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevelent cardiovascular disease. B J Haem 1999; 104: 246-57.
41. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titres of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994; 14: 605-16.
42. Saxena U, Goldberg IJ. Endothelial cells and atherosclerosis: lipoprotein metabolism, matrix interaction and monocyte recruitement. Curr Opin Lipidol 1994; 5: 316-22.
43. Hedriks WL, van der Boom H, van Vark LC, Havekes LM. Lipoprotein lipase stimulates the binding and uptake of moderately oxidizable low-density lipoprotein by J774 macrophages. Biochem J 1996; 314: 563-8.